Review




Structured Review

Addgene inc ythdf2
Figure 1. m6A characteristics after MT treatment in aged mice (A) Representative ovarian histology of 2-month-old mice (young), MT-fed 12- month-old mice (aged + MT), and control 12-month-old mice (Aged). The primary and secondary follicle stages (marked with PF and SF, re spectively) are marked by black arrows. Scale bars, 200 μm (upper) and 20 μm (lower). (B) Quantification of different types of follicles in ovaries from young, aged, and aged + MT mice. Primordial, primary, secondary, corpus luteum, and antral follicles (marked with PmF, PF, SF, CL, and AF, respectively) were counted. n.s., not significant; *P < 0.05. (C) Quantification of the corpus luteum in ovaries from young, aged, and aged + MT mice. (D) Violin plot showing the level of m6A in the ovaries of young, aged and aged + MT mice. n = 5, **** P < 0.0001. (E) Volcano plot showing m6A-modified differentially expressed genes (DEGs) in the ovaries of aged and aged + MT mice (P value < 0.05 and fold change > 2). Down regulated (blue), upregulated (red), and unchanged (gray) genes are indicated. (F) Correlation analysis of 566 m6A DEGs among aged and aged + MT mice. (G) Gene Ontology (GO), KEGG, and Reactome (REAC) pathway analyses of m6A-modified differentially expressed genes. (H) GSEA pathway analysis of the cell cycle. (I,J) Immunofluorescence staining of ovarian GCs from young, aged and aged + MT mice, showing <t>YTHDF2</t> (red) and DAPI (blue). Scale bar, 50 μm. ***P < 0.001.
Ythdf2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf2/pm40495659-103-2-18?v=Addgene+inc
Average 94 stars, based on 15 article reviews
ythdf2 - by Bioz Stars, 2026-08
94/100 stars

Images

1) Product Images from "Melatonin mitigates ovarian aging through regulation of the YTHDF2/m 6 A/UBE3C axis."

Article Title: Melatonin mitigates ovarian aging through regulation of the YTHDF2/m 6 A/UBE3C axis.

Journal: Acta biochimica et biophysica Sinica

doi: 10.3724/abbs.2025090

Figure 1. m6A characteristics after MT treatment in aged mice (A) Representative ovarian histology of 2-month-old mice (young), MT-fed 12- month-old mice (aged + MT), and control 12-month-old mice (Aged). The primary and secondary follicle stages (marked with PF and SF, re spectively) are marked by black arrows. Scale bars, 200 μm (upper) and 20 μm (lower). (B) Quantification of different types of follicles in ovaries from young, aged, and aged + MT mice. Primordial, primary, secondary, corpus luteum, and antral follicles (marked with PmF, PF, SF, CL, and AF, respectively) were counted. n.s., not significant; *P < 0.05. (C) Quantification of the corpus luteum in ovaries from young, aged, and aged + MT mice. (D) Violin plot showing the level of m6A in the ovaries of young, aged and aged + MT mice. n = 5, **** P < 0.0001. (E) Volcano plot showing m6A-modified differentially expressed genes (DEGs) in the ovaries of aged and aged + MT mice (P value < 0.05 and fold change > 2). Down regulated (blue), upregulated (red), and unchanged (gray) genes are indicated. (F) Correlation analysis of 566 m6A DEGs among aged and aged + MT mice. (G) Gene Ontology (GO), KEGG, and Reactome (REAC) pathway analyses of m6A-modified differentially expressed genes. (H) GSEA pathway analysis of the cell cycle. (I,J) Immunofluorescence staining of ovarian GCs from young, aged and aged + MT mice, showing YTHDF2 (red) and DAPI (blue). Scale bar, 50 μm. ***P < 0.001.
Figure Legend Snippet: Figure 1. m6A characteristics after MT treatment in aged mice (A) Representative ovarian histology of 2-month-old mice (young), MT-fed 12- month-old mice (aged + MT), and control 12-month-old mice (Aged). The primary and secondary follicle stages (marked with PF and SF, re spectively) are marked by black arrows. Scale bars, 200 μm (upper) and 20 μm (lower). (B) Quantification of different types of follicles in ovaries from young, aged, and aged + MT mice. Primordial, primary, secondary, corpus luteum, and antral follicles (marked with PmF, PF, SF, CL, and AF, respectively) were counted. n.s., not significant; *P < 0.05. (C) Quantification of the corpus luteum in ovaries from young, aged, and aged + MT mice. (D) Violin plot showing the level of m6A in the ovaries of young, aged and aged + MT mice. n = 5, **** P < 0.0001. (E) Volcano plot showing m6A-modified differentially expressed genes (DEGs) in the ovaries of aged and aged + MT mice (P value < 0.05 and fold change > 2). Down regulated (blue), upregulated (red), and unchanged (gray) genes are indicated. (F) Correlation analysis of 566 m6A DEGs among aged and aged + MT mice. (G) Gene Ontology (GO), KEGG, and Reactome (REAC) pathway analyses of m6A-modified differentially expressed genes. (H) GSEA pathway analysis of the cell cycle. (I,J) Immunofluorescence staining of ovarian GCs from young, aged and aged + MT mice, showing YTHDF2 (red) and DAPI (blue). Scale bar, 50 μm. ***P < 0.001.

Techniques Used: Control, Modification, Immunofluorescence, Staining

Figure 2. MT downregulates m6A levels in KGN cells by increasing YTHDF2 expression (A,B) Cell senescence was detected by SA-β-galacto sidase (SA-β-gal) staining in KGN cells under different conditions: without H2O2 (NC), with H2O2 treatment (400 μM, 12 h), and with H2O2 treatment in the presence of MT (300 μM, 12 h). Scale bar, 40 μm. (C, D) KGN cell apoptosis was detected via terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Scale bar, 50 μm. (E) m6A dot blot analysis to assess m6A levels in KGN cells under different conditions: without H2O2 (NC), with H2O2 treatment, and with H2O2 treatment in the presence of MT. (F,G) Western blot analysis showing YTHDF2 expression in KGN cells. (H, I) Western blot analysis of YTHDF2 expression in scramble control, YTHDF2 knockdown (shYTHDF2) and MT-treated (300 μM, 12 h) KGN cells in the absence of H2O2 exposure. (J, K) Cell senescence was detected by SA-β-gal staining in scramble control-, shYTHDF2- and MT-treated KGN cells in the absence of H2O2 exposure. Scale bar, 40 μm. (L,M) Cell senescence detected by SA-β-gal staining in NC, H2O2-treated, and YTHDF2- overexpressing KGN cells under H2O2 exposure. Scale bar, 40 μm. Dot blot analysis of m6A levels in scramble control, shYTHDF2- and MT-treated KGN cells in the absence of H2O2 exposure. *P < 0.05, ****P < 0.0001.
Figure Legend Snippet: Figure 2. MT downregulates m6A levels in KGN cells by increasing YTHDF2 expression (A,B) Cell senescence was detected by SA-β-galacto sidase (SA-β-gal) staining in KGN cells under different conditions: without H2O2 (NC), with H2O2 treatment (400 μM, 12 h), and with H2O2 treatment in the presence of MT (300 μM, 12 h). Scale bar, 40 μm. (C, D) KGN cell apoptosis was detected via terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Scale bar, 50 μm. (E) m6A dot blot analysis to assess m6A levels in KGN cells under different conditions: without H2O2 (NC), with H2O2 treatment, and with H2O2 treatment in the presence of MT. (F,G) Western blot analysis showing YTHDF2 expression in KGN cells. (H, I) Western blot analysis of YTHDF2 expression in scramble control, YTHDF2 knockdown (shYTHDF2) and MT-treated (300 μM, 12 h) KGN cells in the absence of H2O2 exposure. (J, K) Cell senescence was detected by SA-β-gal staining in scramble control-, shYTHDF2- and MT-treated KGN cells in the absence of H2O2 exposure. Scale bar, 40 μm. (L,M) Cell senescence detected by SA-β-gal staining in NC, H2O2-treated, and YTHDF2- overexpressing KGN cells under H2O2 exposure. Scale bar, 40 μm. Dot blot analysis of m6A levels in scramble control, shYTHDF2- and MT-treated KGN cells in the absence of H2O2 exposure. *P < 0.05, ****P < 0.0001.

Techniques Used: Expressing, Staining, TUNEL Assay, Dot Blot, Western Blot, Control, Knockdown

Figure 3. YTHDF2 regulates the m6A level of UBE3C RNA to affect the level of UBE3C expression (A) Correlation analysis of the m6A levels of ubiquitin protein ligases in aged and aged + MT mice. (B) MeRIP‒qPCR analysis showing the relative mRNA expression levels of ubiquitin-related genes in NC, H2O2 and H2O2+MT KGN cells. (C,D) Western blot analysis showing the expressions of YTHDF2, P53, and UBE3C in NC, H2O2 and H2O2 + MT KGN cells. (E,F) Western blot analysis showing the expression of YTHDF2 in scramble-, YTHDF2-knockdown- and MT-treated KGN cells under H2O2-untreated conditions. (G, H) Cell senescence was detected by SA-β-gal staining under H2O2-untreated conditions. Scale bar, 40 μm. (I,J) Cell senescence detected by SA-β-gal staining in NC, H2O2-treated, and UBE3C-overexpressing KGN cells under H2O2 exposure. Scale bar, 40 μm.
Figure Legend Snippet: Figure 3. YTHDF2 regulates the m6A level of UBE3C RNA to affect the level of UBE3C expression (A) Correlation analysis of the m6A levels of ubiquitin protein ligases in aged and aged + MT mice. (B) MeRIP‒qPCR analysis showing the relative mRNA expression levels of ubiquitin-related genes in NC, H2O2 and H2O2+MT KGN cells. (C,D) Western blot analysis showing the expressions of YTHDF2, P53, and UBE3C in NC, H2O2 and H2O2 + MT KGN cells. (E,F) Western blot analysis showing the expression of YTHDF2 in scramble-, YTHDF2-knockdown- and MT-treated KGN cells under H2O2-untreated conditions. (G, H) Cell senescence was detected by SA-β-gal staining under H2O2-untreated conditions. Scale bar, 40 μm. (I,J) Cell senescence detected by SA-β-gal staining in NC, H2O2-treated, and UBE3C-overexpressing KGN cells under H2O2 exposure. Scale bar, 40 μm.

Techniques Used: Expressing, Ubiquitin Proteomics, Western Blot, Knockdown, Staining

Figure 4. UBE3C upregulates P53 ubiquitination to delay aging (A) Western blot analysis was used to verify the level of P53 ubiquitination in the immunoprecipitates after H2O2 and MT treatment. (B,C) Western blot analysis was used to verify the expressions of P53 and UBE3C after UBE3C was knocked down. (D) qRT-PCR analysis showing the mRNA expression of P53 after UBE3C knockdown. n.s., not significant; ***P < 0.001; ****P < 0.0001. (E,F) Western blot analysis was used to detect the protein expressions of P53 and UBE3C in UBE3C-knockdown and YTHDF2-over expressing KGN cells. (G) Western blot analysis was used to verify the level of P53 ubiquitination in the immunoprecipitates of UBE3C-over expressing and YTHDF2-knockdown KGN cells treated with MG132. (H) Model of the mechanism by which melatonin alleviates ovarian aging in an m6A-dependent manner.
Figure Legend Snippet: Figure 4. UBE3C upregulates P53 ubiquitination to delay aging (A) Western blot analysis was used to verify the level of P53 ubiquitination in the immunoprecipitates after H2O2 and MT treatment. (B,C) Western blot analysis was used to verify the expressions of P53 and UBE3C after UBE3C was knocked down. (D) qRT-PCR analysis showing the mRNA expression of P53 after UBE3C knockdown. n.s., not significant; ***P < 0.001; ****P < 0.0001. (E,F) Western blot analysis was used to detect the protein expressions of P53 and UBE3C in UBE3C-knockdown and YTHDF2-over expressing KGN cells. (G) Western blot analysis was used to verify the level of P53 ubiquitination in the immunoprecipitates of UBE3C-over expressing and YTHDF2-knockdown KGN cells treated with MG132. (H) Model of the mechanism by which melatonin alleviates ovarian aging in an m6A-dependent manner.

Techniques Used: Ubiquitin Proteomics, Western Blot, Quantitative RT-PCR, Expressing, Knockdown



Similar Products

91
MedChemExpress ythdf2
Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; <t>YTHDF2,</t> YTH domain family 2.
Ythdf2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf2/pmc13007997-102-48-54?v=MedChemExpress
Average 91 stars, based on 1 article reviews
ythdf2 - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

96
Proteintech 189 ythdf2
Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; <t>YTHDF2,</t> YTH domain family 2.
189 Ythdf2, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf2/pm41917949-100-13-16?v=Proteintech
Average 96 stars, based on 1 article reviews
189 ythdf2 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc immunohistochemistry ihc
Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; <t>YTHDF2,</t> YTH domain family 2.
Immunohistochemistry Ihc, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf2/pm41872151-95-0-17?v=Cell+Signaling+Technology+Inc
Average 95 stars, based on 1 article reviews
immunohistochemistry ihc - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

96
Proteintech ◦ c alkbh5 1 1000 16837 1 ap proteintech anti ythdf2 1 400 24744 1 ap proteintech bcat2 1 100 16417 1 ap proteintech gpx4 1 100 df6701 affinity
Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; <t>YTHDF2,</t> YTH domain family 2.
◦ C Alkbh5 1 1000 16837 1 Ap Proteintech Anti Ythdf2 1 400 24744 1 Ap Proteintech Bcat2 1 100 16417 1 Ap Proteintech Gpx4 1 100 Df6701 Affinity, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf2/pm41926795-102-16-20?v=Proteintech
Average 96 stars, based on 1 article reviews
◦ c alkbh5 1 1000 16837 1 ap proteintech anti ythdf2 1 400 24744 1 ap proteintech bcat2 1 100 16417 1 ap proteintech gpx4 1 100 df6701 affinity - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Proteintech anti ythdf2
Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; <t>YTHDF2,</t> YTH domain family 2.
Anti Ythdf2, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf2/pm41926795-78-40-43?v=Proteintech
Average 96 stars, based on 1 article reviews
anti ythdf2 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Proteintech ythdf2
Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; <t>YTHDF2,</t> YTH domain family 2.
Ythdf2, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf2/pm41850427-98-4-16?v=Proteintech
Average 96 stars, based on 1 article reviews
ythdf2 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Proteintech ythdf3 antibody
Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; <t>YTHDF2,</t> YTH domain family 2.
Ythdf3 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf2/pm41803297-239-37-27?v=Proteintech
Average 96 stars, based on 1 article reviews
ythdf3 antibody - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Proteintech ythdf2 antibody
Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; <t>YTHDF2,</t> YTH domain family 2.
Ythdf2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf2/pm41803297-239-32-27?v=Proteintech
Average 96 stars, based on 1 article reviews
ythdf2 antibody - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

Image Search Results


Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; YTHDF2, YTH domain family 2.

Journal: International Journal of Molecular Medicine

Article Title: m 6 A in adipose tissue inflammation: A novel regulator of obesity and metabolic diseases (Review)

doi: 10.3892/ijmm.2026.5795

Figure Lengend Snippet: Role of m 6 A in adipogenesis. Insufficient adipogenesis in adipose tissue leads to persistent, chronic inflammation. m 6 A modification plays a crucial role in all stages of adipogenesis, from commitment to terminal differentiation. During commitment, METTL3 promotes lipogenic differentiation in BMSCs by regulating the m 6 A levels of PTH1R and JAK1, whereas silencing METTL14 reduces the expression of SMAD1, inhibiting BMSC proliferation. During terminal differentiation, m 6 A regulates MCE and the transition to mature adipocytes. FTO influences key genes such as ATG5, ATG7 and JAK2, affecting autophagy, STAT3 phosphorylation and adipogenesis. FTO knockout increases the m 6 A levels of CCND1 and CDK2, blocking MCE. m 6 A, N6-methyladenine; METTL, methyltransferase-like; PTH1R, parathyroid hormone 1 receptor; JAK, Janus kinase; BMSC, bone marrow mesenchymal stem cell; MCE, mitotic clone amplification; FTO, Fat mass and obesity-associated protein; ATG, autophagy-related; STAT3, signal transducer and activator of transcription 3; CCND1, cyclin D1; CDK2, cyclin-dependent kinase 2; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; YTHDF2, YTH domain family 2.

Article Snippet: In addition, for mitotic clone amplification (MCE) in the early stage of terminal differentiation, the inhibition of FTO expression in 3T3-L1 cells leads to increased m 6 A methylation levels of cyclin D1 (CCND1) and cyclin-dependent kinase 2, the protein expression of which is reduced after recognition by YTHDF2, resulting in blockade of the MCE process and in turn the inhibition of lipogenesis ( ) ( ).

Techniques: Modification, Expressing, Phospho-proteomics, Knock-Out, Blocking Assay, Amplification, Binding Assay